Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Period	TotalRevenue
2016-12-31	$745.69M
2017-12-31	$903.37M
2018-12-31	$1.09B
2019-12-31	$1.17B
2020-12-31	$1.04B
2021-12-31	$1.17B
2022-12-31	$1.11B
2023-12-31	$1.66B
2024-12-31	$1.56B
2025-12-31	$1.48B

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$37.35	+1.49%	1.12M
3
4
5

Alkermes plc (ALKS) Revenue History

Revenue Data

Get Alkermes plc Data in Excel

More ALKS Financial Data